Advances in Rheumatology 2023
This is a fully virtual event
Description
For more than 40 years, “Advances in Rheumatology” has been influential in educating generations of clinicians on over 100 rheumatic conditions, which now encompass the specialty. A collaboration between Harvard Medical School’s two largest teaching hospitals, the Massachusetts General Hospital and Brigham and Women’s Hospital, the course not only focuses on rheumatic diseases, but offers additional perspectives from other medical disciplines, such as pulmonology, dermatology, oncology, ophthalmology, and endocrinology. “Advances in Rheumatology” targets the practicing clinician seeking to enhance their clinical skills and increase their knowledge with the latest breakthroughs in the diagnosis, treatment, and pathophysiology of rheumatic diseases.
This three day livestream course will be a combination of sessions formatted with lectures by leading experts on topics pertaining to their special areas of interest, curbside consultations and panel discussions. Topics include The Year in Rheumatology, updates on Giant Cell Arteritis, Orbital Inflammatory Disease, Systemic Sclerosis, Hemophagocytic Syndrome, the New England Journal of Medicine Clinicopathological Conference (CPC) and various disease focused afternoon sessions such as Lupus, Psoriatic Arthritis and Rheumatoid Arthritis. The full range of rheumatic disease is covered every year over the span of this course.
Target Audience
This activity is intended for Primary Care Physicians, Specialty Physicians, Nurse Practitioners, Physician Assistants, Dermatology, Endocrinology, Family Medicine, Infectious Disease, Internal Medicine, Oncology and Hematology, Ophthalmology, Orthopedics, Pathology, Preventative Medicine, Pulmonary Medicine, Rheumatology, Urology, Allergy and Immunology.
Learning Objectives
Upon completion of Advances in Rheumatology, participants will be able to:
- Evaluate the latest scientific advances in the field of rheumatology.
- Analyze insights from pathology, immunology, and pharmacology that pertain to specific rheumatologic issues.
- Translate the latest developments in the field of rheumatology to clinical practice.
- Integrate new treatment approaches for patients with rheumatic disease.
- Apply new diagnostic techniques in their patient population.
MOC Completion Criteria
Participant completion for MOC points will be reported to the boards at the conclusion of the course.
Please have your ABIM ID available when completing the evaluation at the end of the course.
Instructions: Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) Program
Upon successful completion of this activity, if you wish to receive MOC Part 2 points you will need to enter your ABIM ID number in the post-course evaluation. The Mass General Brigham Office of Continuing Professional Development will verify completion of your activity and report to the ABIM. Diplomates must check their ABIM Portfolio for confirmation of your MOC Part 2 points.
MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 22.25 MOC points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Funding
Advances in Rheumatology 2023 has received support in the form of an educational grant from the following companies:
AstraZeneca Pharmaceuticals
Bristol Myers Squibb
Janssen Biotech,Inc., administered by Janssen Scientific Affairs, LLC
Novartis
Additional Information
Massachusetts General Hospital, Brigham and Women's Hospital, & Mass General Brigham
Friday, October 13, 2023 | 7:00am - 5:00pm
7:00am | Registration for Advances in Rheumatology |
7:30 | The Year in Clinical Rheumatology | John H. Stone, MD, MPH |
8:30 | Giant Cell Arteritis & Polymyalgia Rheumatica: Answering the Currently Critical Questions | Christian Dejaco, MD, PhD, MBA |
9:30 | Morning Break |
9:45 | ANCA-Associated Vasculitis: The Nephrologist’s Perspective | Andreas Kronbichler, MD |
10:45 | New England Journal of Medicine Clinicopathologic Conference | Luke Chen, MD; John H. Stone, MD, MPH; Ambrose Huang, MD; Judith Ferry, MD; David Dudzinski, MD, JD |
12:00pm | Lunch |
Disease Focused Afternoon Session: Lupus Nephritis | |
1:00 | Important Clinical Outcomes in SLE: How are we doing now? | Michelle Petri, MD, MPH |
1:45 | B Cell Depletion in Lupus: How will it fit into the current treatment paradigms? | David Isenberg, MD, FRCP, FAMS |
2:15 | Break |
2:30 | Calcineurin Inhibitors in SLE Nephritis | Brad Rovin, MD |
3:00 | Novel Treatment Approaches to Lupus | Thomas Dorner, MD |
3:30 | Break |
3:45 | Panel Discussion | Michelle Petri, MD MPH; David Isenberg, MD; Brad Rovin, MD; Thomas Dorner, MD |
5:00pm | Adjourn |
Saturday, October 14, 2023 | 7:45am - 4:30pm
7:45am | Log-In Time |
8:00 | The Pathologies of Inflammatory Myopathy | Andrew Mammen, MD, PhD |
8:45 | Using Autoantibodies to Parse the Inflammatory Myopathies | Julie Paik, MD |
9:45 | Morning Break |
10:15 | Difficult Myopathies | Rohit Aggarwal, MD, MS |
11:00 | Challenges in Lyme Disease | Allen Steere, MD |
12:00pm | Lunch |
Disease Focused Afternoon Session: Psoriasis & Psoriatic Arthritis | |
1:00 | Important Outcomes in Psoriasis/ Psoriatic Arthritis: How are we doing now? | Alexis Ogdie, MD, MSCE |
1:30 | How does a Rheumatologist approach Psoriasis Treatment? | Joseph Merola, MD |
2:00 | Break |
2:15 | Treatment of PsA | Iain B McInnes, CBE, PhD, FRCP, FRSE, FMedSci. |
2:45 | Treatment of Spondylitis | Atul Deodhar, MD |
3:15 | Break |
3:30 | Panel Discussion | Joseph Merola, MD; Iain B McInnes, CBE, PhD, FRCP, FRSE, FMedSci.; Atul Deodhar, MD; Alexis Ogdie, MD, MSCE |
4:30pm | Adjourn |
Sunday, October 15, 2023 | 7:15am - 5:00pm
7:15am | Log-In |
7:30 | Tackling Diffuse Systemic Sclerosis | Ami Shah, MD |
8:30 | How to Approach Limited Scleroderma Now | Laura Hummers, MD |
9:30 | Morning Break |
9:45 | Identifying & Treating the Hemophagocytic Syndrome | Michael Jordan, MD |
10:45 | A Practical Tour through IgG4-Related Disease: Lessons from the patients over 15 years | John H. Stone, MD, MPH |
11:45 | Lunch |
Disease Focused Afternoon Session: Rheumatoid Arthritis | |
1:00pm | Important Outcomes in RA: How are we doing now? | Katherine Liao, MD |
1:30 | Methotrexate in Rheumatoid Arthritis | Michael Weinblatt, MD |
2:00 | Break |
2:15 | Biologics and Jak Inhibition | Ronald van Vollenhofen, MD |
2:45 | How does a Rheumatologist approach RA Treatment? (Europe & USA) | Paul Emery, MD (Europe) & Stanley Cohen, MD (Southwestern USA) |
3:45 | Break |
4:00 | Panel Discussion | Katherine Liao, MD; Ronald Von Vollenhofen, MD; Paul Emery, MD; Stanley Cohen, MD |
5:00pm | Adjourn |
Advances in Rheumatology Course Directors
John H. Stone, MD, MPH
Professor of Medicine, Harvard Medical School;
The Edward A. Fox Chair in Medicine, Massachusetts General Hospital
Michael Weinblatt, MD
John R. Riedman Professor of Medicine, Harvard Medical School;
Co-Director, Clinical Rheumatology,
Associate Director, Center for Arthritis and Joint Diseases,
Brigham and Women’s Hospital
Advances in Rheumatology Speakers
Rohit Aggarwal MD, MS
University of Pittsburgh
Luke Chen, MD
BC Cancer | Vancouver, BC
Stanley Cohen, MD
Christian Dejaco, MD
Brunico Hospital
Atul Deodhar, MD
Oregon Health & Science University
Thomas Dorner, MD
Charite University Hospital
David Dudzinski, MD, JD
Massachusetts General Hospital
Paul Emery, MD
University of Leeds
Judith Ferry, MD
Massachusetts General Hospital
Ambrose Huang, MD
Massachusetts General Hospital
Laura Hummers, MD
Johns Hopkins University
David Isenberg, MD, FRCP, FAMS
University College London
Michael Jordan, MD
Cincinnati Children’s Hospital
Andreas Kronbichler, MD
Medical University Innsbruck
Katherine Liao, MD
Brigham and Women’s Hospital
Andrew Mammen, MD, PhD
National Institute of Health
Iain B McInnes, CBE, PhD, FRCP, FRSE, FMedSci.
University of Glasgow
Joseph Merola, MD
Brigham and Women’s Hospital
Alexis Ogdie, MD, MSCE
University of Pennsylvania
Julie Paik, MD
Johns Hopkins University
Michelle Petri, MD, MPH
Johns Hopkins University
Brad Rovin, MD
Ohio State University
Ami Shah, MD
Johns Hopkins University
Allen Steere, MD
Massachusetts General Hospital
Ronald van Vollenhofen, MD
University of Amsterdam
In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Mass General Brigham designates this live activity for a maximum of 22.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 22.25 ABIM MOC II
- 22.25 AMA PRA Category 1 Credit™
- 22.25 Participation
Price
This is a fully virtual event
Registration Type | Full Registration Fee |
---|---|
Physician | $600.00 |
Resident/Fellow | $150.00 |
Nurse | $300.00 |
Other Allied Healthcare Professionals (Pharmacists, Physician Assistants, PhD) | $300.00 |
Industry | $800.00 |
Cancellation Policy:
Registrations cancelled on or before September 29, 2023 will be refunded, less a $60 administrative fee. Registrations cancelled after September 29, 2023 will not be refunded.
Contact partnerscpd@partners.org if you require assistance in cancelling your online registration.